We are a pharmaceutical company that develops, produces and markets specialized drugs focusing on the respiratory treatment categories. By owning strong RD team and the superior HFA MDI platforms with facilities at the high level as EMA and US FDA standard, we are not only supply high barrier generic drugs but also challenge 505b2 and new combination drug for obstructive airway diseases. We founded in 2010 in Taiwan as the subsidiary of Synmosa Group and Synmosa is one of the leading pharmaceutical companies in Taiwan. In 2017, we opened a new manufacturing site, which is a dedicated respiratory drug products manufacturing plant, for promoting the product exportation and capacity expansion. This manufacturing site can offer 15 million MDI and 1.5million DPI products per year. Simultaneously, we registered as emerging stocks in July 2014 and going to IPO in 2018. Our mission is to provide Innovation, Quality, Professional and Care products and services to patients and customers.